Head-to-head · WeighScore
Big Easy Weight Loss vs LumiMeds
By GLP-1 ScorecardUpdated
Score comparison
Big Easy Weight Loss has the higher recorded score — 75.3/100 to 63.2/100.
Big Easy Weight Loss grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Big Easy offers scheduled physician appointments and compounded GLP-1 packages priced by pharmacy and preparation.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Big Easy Weight Loss | LumiMeds |
|---|---|---|
| WeighScore | 75.3/100 | 63.2/100 |
| Grade | C | C |
| Site position | #58 | #292 |
| Semaglutide | $495 per 12 weeks; pricing also shows $399 starter/$495 regular, with pharmacy-specific options. | $133/mo (starting dose, compounded) |
| Tirzepatide | $599 per 12 weeks on the product page; pricing starts at $469 for a separate pharmacy-specific offer. | $133/mo (starting dose, compounded) |
| Coverage | All-states claim; confirm physician eligibility and pharmacy shipping restrictions. | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #58 · C
Strengths
- Publishes package and starter prices for comparison before requesting a pharmacy-specific quote.
- Lists pharmacy shipping restrictions; published turnaround ranges differ.
- Names its partner compounding pharmacies and a Chief Medical Officer
What to consider
- Priced as 10 to 12-week packages rather than a simple monthly fee
- New-patient pricing is promotional and may rise on renewal
Site position #292 · C
FDAWarning letter issued to Lumimeds in September 2025. See the FDA warning-letter database.
Strengths
- Aggressively low monthly pricing
- Both semaglutide and tirzepatide available
- Compounded GLP-1 access
What to consider
- Limited public information on program details
- FDA issued Lumimeds a warning letter in September 2025; the letter is public in FDA's warning-letter database
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.